Impaired renal function was also among the independent predictors of use, and indeed GLP-1 RA can be used in chronic kidney disease with an eGFR ≥15 mL/min/1.73 m2, while metformin is contraindicated with an eGFR <30 mL/min/1.73 m2. Here, GLP1R is linked to chronic kidney disease.